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Biomarkers of bacterial translocation in advanced chronic liver 
disease: the key to individualizing prognosis
Avik Majumdar, Emmanuel Tsochatzis
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Th e management of patients with liver cirrhosis has evolved 
signifi cantly in the past decade. No longer considered as having 
an invariably poor outcome, the need for better risk stratifi cation 
and prognostic models for this patient group has become 
increasingly apparent [1-3]. Th e defi nition and use of the term 
“cirrhosis” per se is also under scrutiny, with the recent Baveno VI 
consensus guidelines suggesting that the term “advanced chronic 
liver disease” (ACLD) should be used interchangeably [4]. Th is 
highlights the ongoing paradigm shift  where advanced fi brosis 
and cirrhosis are perceived as two oft en clinically indistinguishable 
points on the same spectrum, with both attributing the risk of 
developing complications of chronic liver disease.
Portal hypertension has long been recognized as the main 
pathophysiological process governing the prognosis of patients 
with ACLD. However, the development of clinical signs of 
portal hypertension is an event already too late in the clinical 
trajectory of patients. Th is is illustrated by the substantial 
increase in the 1-year mortality of patients from 3.4% to 20% 
for stage 2 and stage 3 ACLD respectively, with the distinction 
between these stages being the development of ascites [5,6]. 
Earlier identifi cation of those at risk of disease progression is 
therefore urgently needed.
Th e importance of bacterial translocation as an underlying 
mechanism for the clinical consequences of ACLD is being 
increasingly recognized. Th e migration of bacteria or bacterial 
products from the intestinal lumen to mesenteric lymph nodes 
or other non-intestinal sites is a controlled physiological 
process in healthy individuals. However, this process becomes 
progressively deregulated in the presence of advancing 
chronic liver disease and culminates in pathological bacterial 
translocation (PBT), which in turn results in infl ammation, 
immune activation and eventual clinical sequelae such 
as spontaneous bacteremia and spontaneous bacterial 
peritonitis [7]. Once infection develops in patients with ACLD, 
their 1-year mortality increases four-fold [8,9]. Furthermore, 
the altered infl ammatory response to bacterially derived 
products has been implicated in the development of hepatic 
encephalopathy, hepatorenal syndrome and advancing portal 
hypertension [7,10].
However, no reliable measure of PBT currently exists in the 
cirrhotic population, nor is a quantifi able threshold defi ned 
where bacterial translocation becomes pathologic [7,11,12]. 
Peripheral blood levels of bacterial DNA and endotoxin levels 
have traditionally been used as markers of PBT and have 
been correlated with severity of liver disease, as measured by 
Child-Pugh score. However, the correlation with the degree of 
portal hypertension has been less robust. Th is suggests that an 
alternative mechanism associated with immune activation may 
underlie the pathogenic process of translocation of bacterial 
products, as opposed to viable bacteria [13-15]. A  better 
understanding of the complex interactions between luminal 
bacteria, the innate mucosal defence system and downstream 
immune and infl ammatory responses are required.
In this issue of Annals of Gastroenterology, Kaltsa et al 
investigate the role of human beta defensin-1 (hBD-1), an 
intestinal mucosal antimicrobial peptide, as a surrogate 
marker of pathological bacterial translocation using the 
pattern-recognition receptor, soluble CD14 (sCD14), as a 
reference  [16]. sCD14 is expressed primarily by monocytes 
and binds bacterial lipopolysaccharide (LPS) in the presence of 
LPS binding protein (LBP). Elevated concentrations of sCD14 
have been previously demonstrated in patients with cirrhosis, 
but have not been widely validated as a marker of PBT [17,18].
In this study, the systemic expression of hBD-1 expression 
was investigated via peripheral vein sampling with a subset 
of patients undergoing hepatic vein sampling. Real-time 
PCR of the DEFB1 gene (which encodes hBD-1) and other 
antimicrobial peptide genes from terminal ileal and colonic 
biopsies were obtained. Th ree cohorts of patients were 
compared; cirrhosis, non-cirrhotic chronic viral hepatitis 
and healthy controls who were age- and gender-matched. Th e 
cirrhosis group comprised 51  patients of various etiologies 
and was defi ned by the presence of clinical decompensation, 
or in the four patients who had compensated disease, either 
a consistent liver biopsy or a liver stiff ness measurement of 
greater than 12kPa. In contrast, where biopsies were available 
for the chronic viral hepatitis group, patients had minimal liver 
fi brosis (Ishak Stage 0-1).
Kaltsa et al found higher plasma concentrations of hBD-1 in 
cirrhotic patients compared to both other groups, a diff erence 
that was sustained when cirrhotic viral hepatitis patients were 
compared to non-cirrhotic viral hepatitis patients. Levels of 
sCD14 signifi cantly correlated with hBD-1 in the hepatic 
venous blood of cirrhotic patients resulting in a Spearman r 
of 0.6 (P=0.0045) but not in the peripheral blood (P=0.0528); 
however this could be due to a type  II error. Interestingly, 
LBP correlated well with sCD14 in peripheral blood (r=0.5, 
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P=0.0021), however this was in an undefi ned subset of 
cirrhotic patients. Conversely, there was no increased mucosal 
expression of antimicrobial peptide genes, including DEFB1, in 
the cirrhotic group compared with healthy controls. Th is could 
be due to a number of confounding issues such as variable 
intestinal sites of expression of hBD-1 or extraintestinal 
expression, as has been described in monocytes and platelets.
Although the study by Kaltsa et al has a number of 
limitations, including the non-robust defi nitions of study 
cohorts, the lack of consistency of tests performed amongst 
all recruited patients and the heterogeneous group of cirrhotic 
patients with an under-representation of non-alcoholic fatty 
liver disease, the authors should be commended in aiming to 
identify a much needed surrogate of PBT. Th e pursuit of an 
endogenous antimicrobial peptide expressed in plasma is a 
valid concept. However, the strength of association of hBD-1 
expression with PBT is hard to justify without bacterial DNA 
levels. Th e absence of a defi ned reference standard for PBT in 
patients with ACLD is a major challenge, however, measuring 
bacterial DNA appears to be the best available at present. Future 
research could include correlating hBD-1 levels with hepatic 
venous pressure gradient, infl ammatory cytokines and hard 
clinical endpoints including decompensation and mortality.
Th e potential applications for a reproducible and reliable 
peripheral biomarker of PBT in ACLD are immense. Similar to 
the advent of non-invasive markers for pre-cirrhotic fi brosis, 
the early identifi cation of those who are at risk of developing 
complications of advanced chronic liver disease will allow 
better risk-stratifi cation and earlier treatment, which ideally 
will translate to better clinical outcomes. Finding these elusive 
biomarkers of PBT may just be the key to unlocking a new era 
in the management of patients with chronic liver disease.
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